Accuracy of TCOM vs NIRS in Predicting Wound Outcomes in Patients Treated With or Without Revascularization
Launched by UNIVERSITY OF KANSAS MEDICAL CENTER · Jan 7, 2020
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Are between the ages of 18-85
- • Presented with a non-healing lower extremity wound and have a Wagner classification for wound healing of grade 1 or 2
- Exclusion Criteria:
- • Wagner grade 3-5
- • Congestive heart failure (CHF) with a left ventrical ejection fraction (LVEF) \< 30%
- • Have had a below the knee drug eluting stent placed (paclitaxel is chemo, can make wounds worse)
About University Of Kansas Medical Center
The University of Kansas Medical Center (KUMC) is a leading academic medical institution dedicated to advancing healthcare through innovative research, education, and clinical practice. As a prominent clinical trial sponsor, KUMC leverages its extensive expertise in diverse medical fields to conduct rigorous clinical research aimed at improving patient outcomes and developing new treatment modalities. With a commitment to ethical standards and patient safety, KUMC collaborates with multidisciplinary teams to facilitate groundbreaking studies that address significant health challenges, ultimately contributing to the advancement of medical knowledge and the enhancement of community health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kansas City, Kansas, United States
Patients applied
Trial Officials
Adam Alli, MD
Principal Investigator
KUMC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials